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bstract
ecent data suggest that the traditional definition of bisphosphonate-associated osteonecrosis of the jaw (ONJ) may exclude patients who
resent with the non-exposed variant of the condition. To test the hypothesis that a proportion of patients with ONJ remain undiagnosed
ecause their symptoms do not conform to the traditional case definition, we did a secondary analysis of data from MISSION (Multicentre
tudy on phenotype, definition and classification of osteonecrosis of the jaws associated with bisphosphonates), a cross-sectional study of
large population of patients with bisphosphonate-associated ONJ who were recruited in 13 European centres. Patients with exposed and
on-exposed ONJ were included. The main aim was to quantify the proportion of those who, according to the traditional case definition,
ould not be diagnosed with ONJ because they had no exposed necrotic bone. Data analysis included descriptive statistics, median regression,
nd Fisher’s exact test. A total of 886 consecutive patients were recruited and 799 were studied after data cleaning (removal or correction of
naccurate data). Of these, 607 (76%) were diagnosed according to the traditional definition. Diagnosis in the remaining 192 (24%) could not
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rticle under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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e adjudicated, as they had several abnormal features relating to the jaws but no visible necrotic bone. The groups were similar for most of
he phenotypic variables tested. To our knowledge this is the first study in a large population that shows that use of the traditional definition
ay result in one quarter of patients remaining undiagnosed. Those not considered to have ONJ had the non-exposed variant. These findings
how the importance of adding this description to the traditional case definition.
2014 The Authors. Published by Elsevier Ltd. on behalf of The British Association of Oral and Maxillofacial Surgeons. This is an open
ccess article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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ntroduction
steonecrosis of the jaws (ONJ) is a potentially severe
nd debilitating adverse reaction to bisphosphonates and
ther antiresorptive agents such as denosumab. It typically
anifests as painful and often infected areas of necrotic
one, and can lead to severe chronic pain and facial dis-
gurement, which can adversely affect the ability to eat
nd speak, and lowers the quality of life.1–3 Its aetiopatho-
enesis remains enigmatic, and hypotheses have focused
n reduced bony turnover, infection, toxicity of the soft-
issue, and antiangiogenesis.1 The epidemiology also remains
nclear, and reported incidence varies widely. Overall, it is
stimated that necrosis can develop in the jaw in about 8–10%
f patients with malignancy who are given high-potency
isphosphonates (such as zoledronic acid) intravenously,
nd in 0.01–0.1% of those with osteoporosis who take
ow-potency bisphosphonates (such as alendronate) orally.
owever, reported rates vary between 0.004% and 51%.2,3
ata relevant to denosumab given subcutaneously in patients
ith metastatic cancer and osteoporosis seem to replicate
hose when high-potency bisphosphonates are given intra-
enously, and low-potency bisphosphonates are taken orally.4
he individual risk of developing ONJ is also affected by
actors such as the cumulative dosage or duration of antire-
orptive treatment, concomitant exposure to antiangiogenic
gents, procedures that affect the jaws such as tooth extrac-
ions, and dental infections.5,6 Management strategies are
argely based on expert opinion rather than experimental
ata.7 Depending on the extent of disease and severity of
ymptoms, infections and pain can be treated conservatively,
r by minimally invasive surgical debridement or aggressive
esection of necrotic bone, or both.7 Outcomes, which typi-
ally vary and are unpredictable, are often poor when disease
s extensive.8
Several authors have suggested that the burden of ONJ
ssociated with antiresorptive agents, is largely under-
stimated, as the disease is often underdiagnosed and
nder-reported.9 This however remains controversial, and
o obtain robust incidence data, some authors of recent
rials have adopted a rigorous process of adjudication
o identify all those who could have the disease.4,10
ecent data suggest that an incomplete case definition,ntroduced a decade ago and based only on clinical
vidence of exposed necrotic bone, could have con-
ributed to epidemiological estimates being inconsistent
P
2
tecause it excluded cases with no obviously exposed
one.9,11–18
We did a multicentre study of the clinical phenotype
f ONJ in a large group of patients to test the hypothesis
hat use of the traditional case definition by the American
ssociation of Oral and Maxillofacial Surgeons (AAOMS)7
nd the American Society for Bone and Mineral Research
ASBMR),19 which has largely been adopted in previous
tudies, results in a proportion of patients remaining undiag-
osed. Our main aim was to estimate the number of patients
ho would not be diagnosed with ONJ because of their phe-
otype, and more specifically, because of the absence of
xposed necrotic bone.
ethods
tudy design
e did a secondary analysis of a multicentre cross-
ectional study known as MISSION (Multicentre study on
henotype, defInition, and claSSification of osteonecrosIs
f the jaws associated with bisphosphONates),20 which
as reported according to STROBE (Strengthening the
eporting of Observational Studies in Epidemiology)
ecommendations.21
etting
esearchers at the Universities of Verona and Palermo (Italy),
nd University College, London (UK) designed the study
nd sent a collaboration proposal to Italian centres of oral
edicine and oral or maxillofacial surgery with a spe-
ial interest in the diagnosis and management of ONJ. Of
he 13 sites that contributed to MISSION, 10 agreed to
articipate. Full details of MISSION have been reported
lsewhere.20 The ethics committees of the coordinating and
articipating centres approved the study and the patients’
onsent to participate was obtained where specifically
equired.
nclusion criteriaatients referred to the participating centres between January
004 and December 2011 were eligible for MISSION if
hey had previously had, or were currently having treatment
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ith bisphosphonates and they had no history of radiothe-
apy to the jaws. Those with exposed ONJ (long-standing (8
eeks or more) transmucosal exposure of necrotic bone in the
aw),7,19 or non-exposed ONJ (presence of otherwise unex-
lained pain in the jaws, fistula, swelling, mobile teeth, or
andibular fracture) were eligible.11–13 Non-exposed ONJ
as diagnosed after the exclusion of common diseases of
he jaw such as odontogenic infections and bony disorders
nown to cause similar manifestations.11–13 Other inclusion
riteria of MISSION, which were not relevant to our objec-
ives (such as the availability of computed tomography (CT)
nd no previous history of operations on the jaws), have been
eported elsewhere.20 Cases were assessed at each partici-
ating centre by multidisciplinary teams including specialists
ho prescribe bisphosphonates (oncologists, haematologists,
nd rheumatologists) and specialists in oral medicine or max-
llofacial surgery, or both.
ata collection
e collected data between March and December 2012,
nd retrospectively reviewed hospital notes of consecutive
atients diagnosed with ONJ between January 2004 and
ecember 2011. Clinical data relating to ONJ were extracted
y local researchers at one time point and entered into a
urposely developed electronic case report form. A detailed
escription of all data collected by MISSION has previously
een published.20 For our secondary analysis, we collected
ata on age, sex, indication for use of bisphosphonate, and
ype and cumulative dose, concurrent use of steroids, site of
NJ, presence of pain, history of tooth extraction, and dental
r periodontal infection. The medical statistician responsi-
le for data analysis managed the database and data were
leaned according to standard procedures. Stata 13.1 (Stata
orp, College Station, USA) programs were written to ensure
eproducibility of database management.
tudy aim
he primary aim of MISSION was to investigate the agree-
ent between the AAOMS staging system and CT imaging to
ssess the extent of ONJ disease.20 The aim of our secondary
nalysis was to quantify the proportion of patients who would
ot be considered to have ONJ according to the case definition
T
O
w
r
able 1
omparison of continuous measurements between patients with exposed and non-e
Exposed ONJ
No. of patients Median (IQR)
ge (years) 607 68 (61–75)
oledronate (mg) 484 76 (48–120)
amidronate (mg) 70 2160 (990–4320)
lendronate (mg) 81 13,440 (5880–21,280)
eridronate (mg) 2 724 (648–800)
isedronate (mg) 8 3630 (3080–11,310)
bandronate (mg) 21 3600 (450–18,000)axillofacial Surgery 53 (2015) 13–17 15
f the AAOMS and ASBMR. We also compared selected clin-
cal characteristics of patients with exposed and unexposed
NJ.
tatistical analysis
escriptive statistics are given as median (IQR) for continu-
us variables and as numbers or percentages for categorical
ariables. Categorical variables between groups were com-
ared using Fisher’s exact test, and continuous variables using
edian regression. The latter has been reported to detect the
quality of medians better than non-parametric tests, as non-
arametric tests can make implausible assumptions about the
ocation and shape of the distributions to be compared.22
robabilities of less than 0.05 were considered significant.
tatistical analysis was done using Stata 13.1 and programs
ere written to ensure the reproducibility of statistical anal-
sis.
esults
etails of the study population
verall, 886 consecutive patients were recruited at the 13
tudy centres. Those with missing or conflicting data were
xcluded from analysis (n = 87, 10%) so 799 patients were
ncluded.20 All had been treated with bisphosphonates. A
otal of 607 had exposed, and 192 had non-exposed ONJ. The
atients with exposed ONJ had a median age of 68 years and
ere mostly women (66%); 32% of them had breast cancer
nd 80% had had treatment with zoledronate. Those with
on-exposed ONJ had a median age of 69 years and were
lso mostly women (73%); 33% of them had breast cancer
nd 71% had had treatment with zoledronate. Other clinical
eatures of the 2 groups are shown in Tables 1 and 2.
ssociation between exposed bone, and the AAOMS and
SBMR case deﬁnitionhe symptoms of the 607 (76%) patients who had exposed
NJ fitted the AAOMS and ASBMR criteria. In all, bone
as exposed through the oral mucosa or facial skin. The
emaining 192 (24%) could not be diagnosed using the
xposed osteonecrosis of the jaw (ONJ).
Non-exposed ONJ p value
No. of patients Median (IQR)
192 69 (63–76) 0.33
137 72 (48–132) 0.52
29 2610 (2160–4320) 0.39
44 14,560 (6720–26,860) 0.75
0 – – –
4 7335 (5565–11,115) 0.31
9 2850 (1350–3950) 0.77
16 S. Fedele et al. / British Journal of Oral and Maxillofacial Surgery 53 (2015) 13–17
Table 2
Comparison of categorical measurements between patients with exposed and non-exposed osteonecrosis of the jaw (ONJ).
Exposed ONJ
(n = 607)
Non-exposed
ONJ
(n = 192)
p value
No. (%) No. (%)
Male 206 (34) 51 (27) 0.06
Zoledronate 484 (80) 137 (71) 0.02
Pamidronate 70 (12) 29 (15) 0.21
Alendronate 81 (13) 44 (23) 0.002
Neridronate 2 (<1) 0 – –
Risedronate 10 (2) 5 (3) 0.37
Ibandronate 21 (4) 9 (5) 0.51
Other bisphosphonates 250 (41) 93 (48) 0.08
Steroids 175 (29) 49 (26) 0.41
Mandible 383 (63) 135 (70) 0.07
Maxilla 224 (37) 57 (30) 0.07
Pain 489 (81) 134 (70) 0.003
Cancer (all) 345 (57) 99 (52) 0.21
Breast cancer 192 (32) 64 (33) 0.66
Myeloma 166 (27) 44 (23) 0.26
Osteoporosis 91 (15) 48 (25) 0.002
Tooth extraction 348 (57) 86 (45) 0.003
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oental infection 82 (14)
riteria, as they had no evidence of long-term exposure of
one. The main clinical features of both groups are shown in
ables 1 and 2. Characteristics between groups were mostly
imilar, but differences were significant for an underlying
iagnosis of osteoporosis, treatment with alendronate or zole-
ronate, history of tooth extraction, dental infection, and
resence of pain (Table 2).
iscussion
ur findings clearly show that use of the traditional AAOMS7
nd ASBMR19 case definition results in nearly a quarter of
atients with ONJ remaining undiagnosed. Those who were
ot adjudicated to have ONJ were diagnosed with the non-
xposed variant, the clinical manifestations of which have
een consistently and well described by different groups
f investigators during the last few years.11–13,23 Of note,
lthough some patients’ symptoms seemed to fit the AAOMS
ase description of stage 0 disease classification, they could
ot be diagnosed unless bone was exposed.
Development of an accurate case definition relies on
eticulous phenotyping, and it is essential to understand
he epidemiology of the disease and to design clinical trials.
he most widely adopted case definition of bisphosphonate-
ssociated ONJ (AAOMS7 and ASBMR19) is based on
riteria introduced 10 years ago and states that 3 features
ust be present: exposed bone in the maxillofacial region
hat persists for more than 8 weeks, previous or current treat-
ent with bisphosphonates, and no history of radiation to
he jaws. Cases included in clinical studies have therefore
elied largely on clinical evidence of long-standing necrotic
reas of bone exposed through the mucosa or facial skin.
s
r
p43 (22) 0.004
ince 2008, several independent studies have reported that
NJ does not always present with these features. The non-
xposed variant, which is characterised by a number of other
linical features that develop in the absence of bony exposure,
ncludes otherwise unexplained pain in the jaws, fistula, loose
eeth, swelling, and in advanced cases, pathological fracture
f the mandible.11–18 The AAOMS eventually acknowledged
he existence of these features and included the non-exposed
ariant in its classification as stage 0,7 but they did not change
heir case definition and it continues to focus on clinical evi-
ence of long-standing bony exposure, a paradox highlighted
y other authors who called for it to be changed urgently.16–18
s the definition, and not the revised staging system, tends to
e used to decide whether cases are included in clinical tri-
ls and epidemiological studies, revising the staging system
ithout changing the case definition will not have an impact
n diagnosis.
We compared the main clinical features of diagnosed and
on-diagnosed patients to test whether important character-
stics differed. Many characteristics were similar but some
linical variables, which included underlying treatment with
oledronate, history of tooth extraction before the develop-
ent of osteonecrosis, and pain, were more commonly seen
n patients with exposed ONJ. We speculate that this associ-
tion may reflect the typical features of patients referred to
ur centres during the years when ONJ was first recognised –
or example, those who had been given bisphosphonates
ntravenously and had painful exposed bone after dental
xtraction. We also found that use of alendronate, presence
f osteoporosis, and dental infection were more commonly
een in patients with the non-exposed variant. This again may
eflect the fact that evidence of the development of ONJ in
atients who take bisphosphonates orally for osteoporosis
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as become more robust only in recent years, and dental rec-
mmendations regarding invasive operations and reports on
he characteristics of the non-exposed variant have been pub-
ished. Interestingly, our results confirm a recent observation
rom a smaller single-centre study of 102 patients with ONJ
non-exposed in 14), which suggested that both types belong
o the same disease entity.23
Our paper has a number of strengths, which include the
ize of the study population, the multicentre design, and the
ccurate definition of outcomes. Recruitment of consecutive
atients at the study centres, and accurate data collection
nd analysis to minimise the risk of selection bias are also
trengths. Limitations include retrospective data collection
nd the limited geographical variability as all centres but one
ere located in Italy.
onclusions
ur findings highlight the importance of including the non-
xposed variant in the traditional case definition of ONJ,
articularly in the context of adjudication of cases for clin-
cal trials and epidemiological studies. They also suggest
hat some previous reports may have underestimated the true
ncidence of bony necrosis of the jaw.
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